Lorazepam is not considered safe during pregnancy, but the actual risks are more nuanced than the warning label suggests. The FDA classifies it as a Category D drug, meaning there is evidence of fetal risk, and its labeling states it “may cause fetal damage when administered to pregnant women.” That said, the most recent research paints a less alarming picture than older studies did, and in some cases the risks of stopping the medication abruptly can be just as serious as continuing it.
If you’re currently taking lorazepam and just found out you’re pregnant, or you’re planning a pregnancy and wondering what to do, here’s what the evidence actually shows.
How Lorazepam Reaches the Baby
Lorazepam crosses the placenta readily. Studies measuring drug levels in umbilical cord blood found that the baby’s blood concentration reaches about 73% of the mother’s level. That means the fetus is exposed to a substantial portion of every dose you take. Pregnancy also changes how your body processes the drug: it’s cleared faster and distributed more widely, which can make a given dose feel less effective over time, even without changing the amount you take.
Risk of Birth Defects in the First Trimester
Earlier research raised concerns that benzodiazepines like lorazepam might cause oral cleft defects (cleft lip or palate). More recent and larger studies have not confirmed that link. A population-based study in South Korea that looked specifically at first-trimester benzodiazepine exposure found no increased risk of oral clefts.
The Massachusetts General Hospital National Pregnancy Registry for Psychiatric Medications tracked 151 women who took a benzodiazepine during their first trimester and compared them with 902 women taking other psychiatric medications. Major malformations occurred in 3.21% of the benzodiazepine group and 3.46% of the comparison group, a difference so small it was statistically meaningless. The registry’s conclusion was reassuring: benzodiazepines do not appear to have major effects on fetal development in terms of structural birth defects.
That doesn’t mean the risk is zero. It means that at current evidence levels, the risk of a major birth defect from first-trimester lorazepam exposure appears to be close to the baseline risk that exists in any pregnancy (roughly 3% of all births involve some type of major malformation).
Effects on the Newborn in Late Pregnancy
The better-established risks come from taking lorazepam in the weeks before delivery. Newborns exposed to benzodiazepines near the end of pregnancy can develop temporary withdrawal symptoms after birth. These can include irritability, excessive crying, tremors, jitteriness, difficulty breathing, sleep problems, and muscle weakness (sometimes called “floppy infant syndrome”).
Not every exposed baby develops these symptoms. When they do appear, they typically resolve within a few weeks and are not associated with any long-term effects. Still, they can be frightening for new parents and may require a longer hospital stay for monitoring.
Long-Term Developmental Effects
One of the biggest concerns parents have is whether prenatal benzodiazepine exposure could affect their child’s brain development, potentially increasing the risk of ADHD or autism. Initial studies seemed to suggest a connection. When researchers compared children exposed to benzodiazepines in utero with the general population, they found modestly elevated rates of both conditions.
But a large cohort study published in JAMA Network Open added a critical piece of context. When the same researchers compared exposed children not to the general population but to their own unexposed siblings, the increased risk disappeared entirely. This strongly suggests that the apparent link between benzodiazepine exposure and ADHD or autism was actually explained by shared genetics and family environment, not the medication itself. The mothers who needed benzodiazepines during pregnancy were more likely to carry genetic factors associated with these conditions, and those genetic factors, not the drug, accounted for the higher rates in their children.
Animal studies have shown that sedation drugs affecting the same brain pathways as lorazepam can increase brain cell death in developing primates when used for extended periods. Whether this translates to human pregnancies at typical therapeutic doses remains unclear, but it’s one reason clinicians prefer to use the lowest effective dose for the shortest time possible.
If You’re Currently Taking Lorazepam
Stopping lorazepam suddenly is not safe, pregnant or not. Abrupt discontinuation can cause seizures, severe rebound anxiety, and other withdrawal effects that pose their own risks to both you and a pregnancy. If you and your provider decide to taper off, the process needs to be gradual and carefully managed.
The American Society of Addiction Medicine recommends that if you’re switching to an alternative medication like an SSRI, the new medication should be started six to eight weeks before beginning the taper, since SSRIs take time to reach full effect. During the taper, the goal is to reach the lowest dose possible, particularly to reduce the chance of neonatal withdrawal symptoms if you’ll still be taking lorazepam closer to delivery. Sleep should be monitored closely throughout, since disrupted sleep can worsen anxiety and complicate the tapering process.
Alternatives Worth Discussing
Cognitive behavioral therapy is considered a first-line treatment for anxiety and panic disorder during pregnancy. It carries no pharmacological risk and has strong evidence for generalized anxiety and panic. For many people, it can reduce or replace the need for medication, though it takes time to work and isn’t always accessible.
SSRIs are the most commonly used medication alternative for anxiety during pregnancy and generally carry a more favorable risk profile than benzodiazepines, though they have their own considerations. The right choice depends on the severity of your symptoms, how well you’ve responded to other treatments in the past, and how far along you are in pregnancy.
Weighing the Risks
The FDA’s Category D label makes lorazepam sound categorically dangerous, but the real picture is more balanced. The risk of structural birth defects appears to be minimal based on current registry data. The clearest risk is temporary withdrawal symptoms in newborns exposed late in pregnancy, which resolve on their own. Long-term neurodevelopmental concerns have not held up when researchers accounted for genetic factors.
None of this means lorazepam is recommended during pregnancy. It means the decision involves weighing real but modest medication risks against the very real consequences of untreated severe anxiety or panic disorder, which can include preterm birth, low birth weight, and complications from chronic stress. For some people, staying on a low dose of lorazepam is the least risky option available. For others, tapering off and switching to a safer alternative is achievable and preferable. That calculus is different for every pregnancy.